HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


PDUFA III Deal Includes Risk Management Fees In “Peri-Approval” Phase

This article was originally published in The Tan Sheet

Executive Summary

The FDA/industry PDUFA III agreement includes funding to expand FDA's Office of Drug Safety by 100 full-time equivalent staff positions over five years

You may also be interested in...

White House Eyes Ophthalmologist Roberts For FDA; Frist Is Sponsor

White House interest in Cornell ophthalmologist Calvin Roberts, MD, indicates that the search for a permanent FDA commissioner is continuing

FDA Protocol Reviews Would Include Outside Consultants Under PDUFA III

The PDUFA III agreement between FDA and industry includes a provision that would allow sponsors to request the participation of outside consultants in protocol design meetings

PDUFA III Or Hatch/Waxman II?: Payors Urge Fix For Generic “Loopholes”

Supporters of the generic industry's Hatch/Waxman agenda are eyeing the Prescription Drug User Fee Act reauthorization as a potential vehicle for reform measures

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts